Watch for the full Q3 2026 10-Q filing for complete financials including gross margin, operating expenses, and cash position. The sequential revenue acceleration from two commercial products is a positive signal, but the company remains pre-profitability with a small revenue base.
Price Chart
Executive Summary
Scienture Holdings reported preliminary Q3 2026 revenue of ~$1.22M, up 256% sequentially from Q2 2026's ~$344K, driven by the REZENOPY commercial launch and continued Arbli growth. Separately, Nasdaq confirmed the company regained compliance with the $1.00 minimum bid price rule, removing delisting risk. The filing is a preliminary revenue update only — no EPS or full financials were provided.
Key Financial Metrics
Key Facts
- Preliminary Q3 2026 revenue of approximately $1.22 million, up 256% sequentially from ~$344,000 in Q2 2026
- REZENOPY (naloxone HCl) nasal spray launched commercially in August 2026 with initial wholesale shipments
- Arbli wholesale unit sales increased 74% sequentially with new institutional formulary additions
- Nasdaq confirmed compliance with the $1.00 minimum bid price rule as of October 16, 2026, closing the delisting matter
- Company targets profitability in 2027, citing high gross margins and operating leverage
Financial Impact
Preliminary Q3 2026 revenue of ~$1.22M, up 256% sequentially from ~$344K in Q2 2026
Risk Factors
- Preliminary revenue is unaudited and subject to adjustment in the final 10-Q
- Company still operating at a net loss — profitability target of 2027 is aspirational
- Small revenue base (~$1.22M quarterly) means any single customer or payer disruption could materially impact results
- Cash and cash equivalents were only $3.5M as of March 31, 2026 — may require additional financing
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-047579 |
| Exhibit: ex99-1.htm | 0001493152-26-047579 |
| Document: 0001493152-26-047579-index-headers.html | 0001493152-26-047579 |
| Document: 0001493152-26-047579-index.html | 0001493152-26-047579 |
| Document: 0001493152-26-047579.txt | 0001493152-26-047579 |
| 8-K Data (Synthetic) | 0001493152-26-047579 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 5d ago | Press Release | $2.77 | awaiting T+5 | — | $3.14 (+13.36%) |
Oct 19, 2026 7d ago | 8-K | $3.05 | awaiting T+5 | — | $3.14 (+2.95%) |
Oct 13, 2026 14d ago | Press Release | $3.24 $3.05 | ▲ +5.86% | ▲ +4.71% | $3.14 (+3.09%) |
Oct 7, 2026 19d ago | 8-K | $3.86 $3.38 | ▼ −12.44% | ▼ −12.16% | $3.14 (−18.65%) |
May 29, 2026 21w ago | 8-K | $0.3960 $0.3600 | ▼ −9.09% | ▼ −6.34% | $3.14 (+692.93%) |
May 22, 2026 22w ago | 8-K | $0.4000 $0.3910 | ▼ −2.25% | ▼ −3.46% | $3.14 (+685.00%) |
May 18, 2026 23w ago | Press Release | $0.3940 $0.4000 | ▲ +1.52% | ▼ −0.10% | $3.14 (+696.95%) |
May 5, 2026 24w ago | 8-K | $0.3910 $0.3980 | ▲ +1.79% | ▲ +0.66% | $3.14 (+703.07%) |
Apr 30, 2026 25w ago | 10-K/A | $0.4010 $0.4000 | ▲ +0.25% | ▲ +2.60% | $3.14 (−683.04%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers